Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$16.07M+420.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin J. Knopp
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 172
- Beta
- 0.68
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.93
Financials
Revenue
$16.07M+420.4%Net Income
$-11.89MEBITDA
$-10.59MFree Cash Flow
$3.01MEPS (diluted)
$-0.32Shares Outstanding (diluted)
37.73M+364.6%Operating Expenses
$14.71MCash & Debt
$101.53MRevenue by Segment (annual)
$63.19MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $56.20M | $-36.64M | $-1.01 |
| 2024 | $59.63M | $-72.21M | $-2.12 |
| 2023 | $50.23M | $-36.40M | $-1.13 |
| 2022 | $46.85M | $-33.56M | $-1.07 |
| 2021 | $42.21M | $-22.17M | $-0.79 |
| 2020 | $26.89M | $-12.82M | $-2.35 |
| 2019 | $17.97M | $-13.37M | $-2.02 |
| 2018 | $22.05M | $-7.54M | $-0.93 |
Valuation
MASShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-65.12%Social Signal Score
Mentions (11)
- Newsnewsfilecorp.com·6d ago·Neutral
…itial 2026 Drilling Program at Cerro Colorado Project, Sonora, Mexico Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) ("Masivo" or the "Company") is pleased to report encouraging analytical results from Drill Hole CC-26-001, the first drill hole completed as part of the Company's current exploration program at its Cerro Colorado Project in Sonora, Mexico. CC-26-001 intersected a broad polymetallic mineralized system, includi…
View source ↗ - Newsmarketbeat.com·37d ago·Negative
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates 908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
View source ↗ - Newsgurufocus.com·45d ago·Neutral
Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho
View source ↗ - Newsmarketbeat.com·49d ago·Negative
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection 908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
View source ↗ - Newsmarketbeat.com·52d ago·Negative
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market 908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
View source ↗ - Newsseekingalpha.com·54d ago·Negative
908 Devices Q2: Another Solid Report 908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
908 Devices: Mission Critical Devices Drive Growth 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript 908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Negative
908 Devices Q2 Earnings Call Highlights 908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
View source ↗ - Newszacks.com·56d ago·Negative
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates 908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
View source ↗ - Newsbusinesswire.com·56d ago·Neutral
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety, and defense tech applications, today reported financial results for the quarter ended June 30, 2026. “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA los
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.16 per share
Typical surprise -46.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.32 vs $-0.14miss
- Wed, May 6$-0.22 vs $-0.15miss
- Tue, Mar 3$-0.05 vs $-0.06beat
- Mon, Nov 10$-0.15 vs $-0.12miss
- Tue, Aug 5$-0.36 vs $-0.16miss
- Tue, May 13$-0.22 vs $-0.27beat
Estimates and results for MASS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MASS officers and directors.
- Bought
- —
- Sold
- $9.1m
0 trades
52 trades
- Awm Investment Company, Inc.sold
- Awm Investment Company, Inc.sold
- Awm Investment Company, Inc.sold
- Kenneweg Johnsold
- Kenneweg Johnsold
- Kenneweg Johnsold
- Brown Christopher D.sold
- Griffith Joseph H. Ivsold
48 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MASS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.